ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests whether analyzing circulating tumor DNA in blood can detect minimal residual disease in colorectal cancer patients after surgery or treatment. The approach uses ddPCR to target KRAS G12 and G13 mutations and monitors patients over two years with regular blood draws. It aims to improve risk stratification and guide follow-up or therapy decisions based on MRD status. The study is prospective and conducted at Masaryk Memorial Cancer Institute in the Czech Republic. Primary outcome is early detection of recurrence and better prediction of disease course.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed diagnosis of colorectal cancer (clinical stage II, III, or IV).
* Presence of KRAS gene mutation (specifically G12 or G13 mutations) confirmed in the primary tumor tissue.
* Age 18 years or older at the time of inclusion.
* Patient scheduled for standard primary surgical resection, local treatment, or adjuvant therapy as per institutional guidelines.
* Signed written informed consent to participate in the study.

Exclusion Criteria:

* Absence of target KRAS mutations (G12/G13) in the primary tumor.
* Inability or unwillingness to comply with scheduled blood sampling and follow-up visits.
* Active second primary malignancy that could interfere with ctDNA interpretation.

Where it's running

• Masaryk Memorial Cancer Institute
  Brno, Czech Republic, Czechia Recruiting

Study contacts

• Study coordinator: Igor Kiss, doc. MUDr. Ph.D., MBA
• Email: igor.kiss@mou.cz
• Phone: +42054313111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples

  This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.

  Recruiting at 2 sites Vorarlberg Institute for Vascular Investigation and Treatment · Bregenz, Vorarlberg and 3 other locations · NCT07913802

• Parastomal Hernia After Colorectal Cancer Surgery: Do Radiology Findings Match Quality of Life

  We’re testing how often parastomal hernias appear and change on CT scans after colorectal cancer surgery with a permanent end colostomy, and whether these findings relate to patients’ quality of life.

  Recruiting Region Skane · Malmö, Skåne County · NCT07909148

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.